Odyssey Health Stock Price, News & Analysis

Odyssey Health Inc. (OTCQB: ODYY) is a Nevada-based medical company focused on developing, acquiring and commercializing life-saving and life-enhancing medical products and health-related technologies. According to its SEC filings and company disclosures, Odyssey emphasizes medical solutions that offer an identified technological advantage, superior clinical utility and substantial market opportunity. The company’s mission is to create or acquire distinct technologies and intellectual property and advance them toward regulatory clearance and commercial use.

Odyssey Health operates as a publicly held company whose shares are quoted on the OTCQB market. The company describes its business model as centered on the development or acquisition of unique medical products, engaging third parties to manufacture those products, and distributing them through a mix of third-party and direct channels. Its leadership team is described in filings as having experience in refining technologies and submitting them to appropriate regulatory agencies for marketing approval.

Core medical device portfolio

In its registration statement on Form S-1, Odyssey Health reports development projects in two life-saving technologies: the CardioMap® heart monitoring and screening device and the Save A Life (“SAL”) choking rescue device. These devices are characterized by the company as medical technologies under development intended to address critical health events.

The Save A Life anti-choking device is described in company news as a patented, vacuum-based device designed to remove a lodged mass or bolus from the throat of a choking victim. The device incorporates a pump that creates a vacuum chamber connected to a replaceable or disposable mouthpiece. When inserted into the victim’s mouth, it depresses the tongue to provide a clear, trauma-free application. By pressing a button, the device delivers an instantaneous vacuum intended to dislodge the obstruction without harming the patient, with the application designed to be effective within seconds.

Odyssey has also reported that it retains the CardioMap heart monitoring technology as part of its asset base. In its communications, the company identifies CardioMap as a heart monitoring and screening device, reflecting its focus on cardiovascular assessment technologies.

BreastCheck® sub-licensing and breast health focus

In an 8-K filing and related press releases, Odyssey Health disclosed that it entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc. for exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The agreement is managed through Odyssey’s subsidiary, Odyssey Medical Devices, Inc., and is subject to specified closing conditions.

BreastCheck®, described as a product of Davion Healthcare PLC, is presented as a safe, accurate and low-cost way to routinely monitor for breast abnormalities. It is intended to be used as an adjunct to established procedures such as clinical breast examination and mammography. According to Odyssey’s news releases, abnormalities within the breast can produce additional heat, and BreastCheck® operates by averaging temperature at three areas on each breast. By comparing corresponding areas between the two breasts and entering the results into the BreastCheck® mobile application, users can obtain immediate interpretation of the temperature differences.

The company notes that the BreastCheck® test can be performed at home in approximately 15 minutes, with immediate results that may help identify potential breast abnormalities at an early stage. Odyssey highlights that the technology behind BreastCheck® is FDA registered in the United States and registered with relevant regulatory authorities in the European Union and the United Kingdom. Through the sub-licensing arrangement, Odyssey Medical Devices, Inc. expects to acquire exclusive global marketing and distribution rights, aligning this diagnostic tool with the company’s focus on life-saving and life-enhancing medical solutions.

Historical neurological drug platform and asset sale

Odyssey Health previously developed a neurological drug therapy platform, including a lead concussion drug candidate designated ONP-002 and a candidate for Niemann-Pick Type C disease, along with a proprietary powder formulation and nasal delivery device. Company news and joint announcements with Oragenics, Inc. describe ONP-002 as a fully synthetic, non-naturally occurring neurosteroid under development for the treatment of mild traumatic brain injury (concussion). Preclinical animal studies cited by the company indicated rapid and broad biodistribution throughout the brain, reductions in swelling, inflammation and oxidative stress, and improved behavioral outcomes such as memory, sensory-motor performance and reduced anxiety. A Phase 1 human clinical trial was reported as showing that ONP-002 was safe and well tolerated in healthy subjects.

In a definitive Asset Purchase Agreement with Oragenics, Inc., Odyssey agreed to sell its proprietary neurological drug therapy assets, including ONP-002, the Niemann-Pick C candidate, the powder formulation and the nasal delivery device. An 8-K filing and subsequent news releases confirm that this transaction closed in late 2023. Odyssey received cash payments totaling one million dollars and eight million shares of Oragenics Series F Convertible Preferred Stock, which are recorded as an investment on Odyssey’s balance sheet. Certain members of Odyssey’s management joined Oragenics to lead further development of the neurological pipeline. Odyssey has stated that it retains its other assets and operations, including CardioMap and the Save A Life choking rescue device.

Strategic financing and recurring revenue arrangements

Odyssey Health has disclosed several financing and service arrangements intended to support its operations and growth plans. In a Form 8-K dated November 19, 2025, the company reported entering into a Maintenance Agreement with Mast Hill Fund, L.P. Under this agreement, Odyssey agreed to provide maintenance and related services for a commercial facility from the effective date through the first business day of February 2034. Mast Hill Fund or its designee will pay service fees in accordance with a schedule attached to the agreement, and the filing notes that these fees currently total approximately $245,000 per year.

In connection with the Maintenance Agreement, Odyssey issued a convertible promissory note in the original principal amount of $2,262,000 to Mast Hill Fund in exchange for the service fees to be received. The note bears interest and is convertible into shares of Odyssey common stock at a discount to the volume-weighted average price over a specified period. The company is required to remit service fees received, less direct costs, to Mast Hill Fund as payment on the note until it is paid in full or converted. Odyssey has described this long-term maintenance service contract as creating a stable, recurring revenue stream and contributing to its transition toward sustainable, cash-generating operations.

On the same date, Odyssey entered into a Securities Purchase Agreement with Mast Hill Fund, under which the company may issue a promissory note with a maximum principal amount of up to $25,000,000 in multiple tranches, subject to an original issue discount. Each tranche is convertible into common stock at a formula-based price, and Odyssey issues warrants to Mast Hill Fund with each tranche. The first tranche consisted of a $500,000 principal amount, with net proceeds to Odyssey after discount and fees.

Corporate evolution and capital markets profile

Odyssey Health Inc. was formed as a Nevada corporation on March 19, 2014. The company’s S-1 registration statement notes that the registration statement effecting its initial public offering became effective in July 2015. Odyssey’s principal executive offices are located in Las Vegas, Nevada. Its common stock is quoted on the OTCQB market under the symbol “ODYY,” and the company describes the public market for its shares as having limited liquidity.

In its S-1 filing, Odyssey identifies itself as a smaller reporting company and non-accelerated filer under SEC rules. The company indicates that it may use its public-company status and access to capital markets to support its strategy of acquiring and developing medical technologies and intellectual property. The S-1 also describes a registration of shares for resale related to a Maintenance Agreement and Securities Purchase Agreement with Mast Hill Fund, reflecting the company’s use of structured financing arrangements.

Business model and development approach

Odyssey Health’s filings describe a trans-disciplinary product development approach. The company intends to license, improve and/or develop medical products and then identify and select appropriate distribution channels for each product. It plans to work with third-party research and development firms specializing in medical products to assist in development activities and to apply for trademarks and patents as it develops proprietary technologies.

For distribution, Odyssey states that it will establish agreements with distributors to bring products to market and also undertake its own direct marketing efforts where appropriate. The company emphasizes selection of products and technologies that can be advanced through regulatory pathways and that target significant medical markets. Its portfolio history, including the neurological drug platform sale and its ongoing device projects, illustrates a strategy of acquiring assets, developing them to add value, and then partnering or selling them when monetization opportunities arise.

Position within the medical technology landscape

Across its disclosures, Odyssey Health consistently characterizes its focus as “life-saving” or “life-enhancing” medical solutions. Its projects have spanned emergency interventions such as anti-choking devices, cardiovascular monitoring technologies, at-home breast abnormality screening, and previously, neurological drug therapies for concussion and rare disease. The company’s communications highlight areas where it believes there is unmet medical need or substantial market potential, and where technological features such as non-invasive testing, intranasal delivery, or rapid response capabilities may provide clinical and practical benefits.

By concentrating on medical devices and technologies that can be developed in collaboration with specialized partners and manufactured by third parties, Odyssey aims to operate as a development and commercialization platform rather than a fully integrated manufacturer. Its use of licensing, sub-licensing and asset sale transactions, as seen in the BreastCheck® agreement and the Oragenics asset sale, reflects a flexible approach to structuring ownership and commercialization rights around its portfolio.